Up to $340 million in private placement will fund a pivotal Phase 3 trial of BOT + BAL in MSS colon cancer, targeting a $7B US market. The trial design is FDA-aligned, with interim data expected in 2027 and operations funded through 2031.Original document: Agenus Inc. [AGEN] Press release — Jul. 13…
Up to $340 million in private placement will fund a pivotal Phase 3 trial of BOT + BAL in MSS colon cancer, targeting a $7B US market. The trial design is FDA-aligned, with interim data expected in 2027 and operations funded through 2031.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
